摘要
目的 研究白细胞介素 2 (IL 2 )和白细胞介素 12 (IL 12 )活化脐带血 (ACB)的抗肿瘤效应和重建造血功能 ;探讨ACB性质和杀伤肿瘤细胞的机制。方法 测定ACB杀伤肿瘤细胞的活性 ;应用流式细胞术检测ACB细胞表面分化抗原 ,肿瘤细胞DNA含量及细胞凋亡的表达。结果 活化脐带血与L12 10 细胞、新鲜白血病细胞共同培养后显示有杀伤白血病细胞作用 ,以培养 3~ 4天时最强 ;ACB细胞的CD3、CD8、CD16、CD5 6、CD71、CD95分化抗原表达与新鲜脐带血相比升高显著 (P<0 0 1)。L12 10 细胞、新鲜白血病细胞与ACB培养后分化抗原CD71、CD95表达下降 ,超二倍体、亚二倍体等异倍体减少 ,与对照组相比差异显示有统计学意义 (P <0 0 5 ) ;ACB中CD34+ /CD38-细胞群分化抗原表达与新鲜脐带血相比没有显著性差异 (P >0 0 5 )。结论 ACB具有抗肿瘤效应 ,其中有细胞毒T细胞、自然杀伤细胞的作用 ,也有诱导肿瘤细胞凋亡机制参与 ;ACB还保留有重建造血的功能 ;IL 12ACB比IL
Objective To study the anti tumor effect of IL 2 and Il 12 activated cord blood and its function of hemopoietic reconstruction,and to study the nature of activated cord blood and its tumor cell killing mechanism.Methods The competence of activated cord bllood in killing tumor cells was assayed.The cell surface differentiation antigen of activated cord blood was determined.Results The activated cord blood exhibited the effects of killing leukemia cells when cultured with L 1210 cells and fresh leukemia cells,and this effect reached the highest point in 3~4days after the co culture.The differentiation antigen expression of CD3,CD8,CD16,CD56,CD71,and CD95 of the activated cord blood was increased significantly as compared with those of fresh cord blood ( P< 0 01).After the co culture of L 1210 cell,fresh leukemia cell and activated cord blood,the expression of differentiation antigen CD71 and CD95 dropped significantly.Heteroploid (hyperdiploid and hypodiploid)decreased.The decrease had statistic significance as compared with those of the control ( P< 0 05).The difference between the differentiation antigen expression of the activated cord blood CD34 +/CD38 - cell group and that of the fresh cord blood was not significant( P> 0 05).Conclusion The activated cord blood possesses the anti tumor effects which involve the effect of cytotoxic T cell,that of the natural killer cell and the mechanism of apoptosis.IL 12 activated cord blood is more potent than IL 2 activated blood and the potency can be enhanced when used in combination of both.
出处
《江苏医药》
CAS
CSCD
北大核心
2002年第10期724-726,共3页
Jiangsu Medical Journal
基金
江苏省科委应用基础研究基金 (BJ 960 11)
国际抗癌联盟 (UICC)ICRETT基金 (92 674)